Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?

Gruson, Damien;Pouleur, Anne-Catherine;Hermans, Michel;Ahn, Sylvie;Rousseau, Michel
(2022) Annales d’endocrinologie — Vol. 83, n° 1, p. 78-80 (2022)

Files

Treatmentwithsodium-glucosecotransporter-2inhibitorsinheartfailurepatients.pdf
  • Open Access
  • Adobe PDF
  • 597.73 KB
Download

Details

Authors
Abstract
Inhibitors of sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown effective glucose-lowering effects associated with improved clinical outcomes in diabetic patients and heart failure patients. As SGLT2 inhibitors can increase phosphate levels, they can also modulate FGF-23 production, a hormone directly involved in regulation of bone and mineral metabolism, but also a strong predictor of adverse cardiovascular events. We therefore discuss the relevance of FGF-23 as a companion testing of SGLT2 treatment, in addition to standard clinical biology tests.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Gruson, D., Pouleur, A.-C., Hermans, M., Ahn, S., & Rousseau, M. (2022). Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels? Annales d’endocrinologie, 83(1), 78-80. https://doi.org/10.1016/j.ando.2021.10.003 (Original work published 2022)